1 mg/day of Pls purified from scallop	placebo	Plasma PlsPE	2338	2465	Patients with mild AD showed a significantly greater decrease in plasma PlsPE in the placebo group than in the treatment group.
1 mg/day of Pls purified from scallop	placebo	occurrence of adverse events	1653	1919	In an intention-to-treat analysis including both mild AD (20 ≤ MMSE-J ≤ 23) and MCI (24 ≤ MMSE-J ≤ 27), no significant difference was shown between the treatment and placebo groups in the primary and secondary outcomes, with no severe adverse events in either group.
1 mg/day of Pls purified from scallop	placebo	WMS-R (0 min)	14465	14630	The WMS-R (0 min) and WMS-R (30 min) score each showed a significant improvement in both groups, but there was no statistically significant between-group difference.
1 mg/day of Pls purified from scallop	placebo	occurrence of adverse events	16615	16706	There was no notable difference in the occurrence of adverse events between the two groups.
1 mg/day of Pls purified from scallop	placebo	WMS-R (30 min) In the patients aged 77 years or younger,	15663	15841	In the patients aged 77 years or younger, WMS-R (30 min) increased statistically significantly in the treatment group, showing a significant between-group difference (P = 0.029).
